Top-News

Hoth Therapeutics Aktie News

Aktie
WKN:  A3DZJ0 ISIN:  US44148G2049 US-Symbol:  HOTH Branche:  Biotechnologie Land:  USA
1,205 $
+0,015 $
+1,26%
1,0349 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
13,52 Mio. €
Streubesitz
92,54%
KGV
-0,67
Index-Zuordnung
-

Hoth Therapeutics News

11.06.25 - PR Newswire
Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities
Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities PR Newswire
05.06.25 - PR Newswire
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
Hoth Therapeutics to Spotlight HT-001 in Investor-​Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities PR Newswire
12.05.25 - PR Newswire
/C O R R E C T I O N -- Hoth Therapeutics, Inc./
/C O R R E C T I O N -- Hoth Therapeutics, Inc./ PR Newswire
17.04.25 - PR Newswire
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform PR Newswire
15.04.25 - PR Newswire
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial PR Newswire
02.04.25 - PR Newswire
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ PR Newswire
31.03.25 - PR Newswire
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage PR Newswire
26.03.25 - PR Newswire
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation PR Newswire
18.03.25 - PR Newswire
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death ...
10.03.25 - PR Newswire
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need PR Newswire
05.03.25 - PR Newswire
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-​Associated Papulopustular Eruptions Findings to be Presented at the American Academy of ...
04.03.25 - PR Newswire
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-​Changer in Obesity Treatment and Reduced Fatty Liver Disease PR Newswire
10.02.25 - PR Newswire
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic PR Newswire
24.01.25 - PR Newswire
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire
21.01.25 - PR Newswire
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications PR Newswire
17.01.25 - PR Newswire
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 PR Newswire
08.01.25 - PR Newswire
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries PR Newswire
07.01.25 - PR Newswire
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities PR Newswire
26.12.24 - PR Newswire
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »